HRP950532B1 - Apolipoprotein-b synthesis inhibitors - Google Patents

Apolipoprotein-b synthesis inhibitors

Info

Publication number
HRP950532B1
HRP950532B1 HR950532A HRP950532A HRP950532B1 HR P950532 B1 HRP950532 B1 HR P950532B1 HR 950532 A HR950532 A HR 950532A HR P950532 A HRP950532 A HR P950532A HR P950532 B1 HRP950532 B1 HR P950532B1
Authority
HR
Croatia
Prior art keywords
apolipoprotein
synthesis inhibitors
inhibitors
synthesis
Prior art date
Application number
HR950532A
Other languages
English (en)
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Robert Jozef Maria Handrickx
Luc Alfons Leo Van Der Eycken
Didier Robert Guy G Courcelles
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,304 external-priority patent/US5521186A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP950532A2 publication Critical patent/HRP950532A2/hr
Publication of HRP950532B1 publication Critical patent/HRP950532B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR950532A 1994-10-27 1995-10-27 Apolipoprotein-b synthesis inhibitors HRP950532B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203120 1994-10-27
US08/455,304 US5521186A (en) 1994-10-27 1995-05-31 Apolipoprotein-β synthesis inhibitors

Publications (2)

Publication Number Publication Date
HRP950532A2 HRP950532A2 (en) 1997-08-31
HRP950532B1 true HRP950532B1 (en) 2001-06-30

Family

ID=26136684

Family Applications (1)

Application Number Title Priority Date Filing Date
HR950532A HRP950532B1 (en) 1994-10-27 1995-10-27 Apolipoprotein-b synthesis inhibitors

Country Status (30)

Country Link
US (1) US5929075A (fr)
EP (1) EP0788496B1 (fr)
JP (1) JP3025907B2 (fr)
KR (1) KR100227231B1 (fr)
CN (1) CN1068000C (fr)
AP (1) AP779A (fr)
AT (1) ATE198889T1 (fr)
AU (1) AU697744C (fr)
BG (1) BG63694B1 (fr)
BR (1) BR9509436A (fr)
CA (1) CA2203274C (fr)
CY (1) CY2256B1 (fr)
CZ (1) CZ286476B6 (fr)
DE (3) DE122007000005I2 (fr)
DK (1) DK0788496T3 (fr)
ES (1) ES2155535T3 (fr)
FI (1) FI119548B (fr)
GR (1) GR3035519T3 (fr)
HR (1) HRP950532B1 (fr)
HU (1) HU219862B (fr)
IL (1) IL115771A (fr)
LU (1) LU91306I2 (fr)
NO (1) NO311937B1 (fr)
NZ (1) NZ295353A (fr)
OA (1) OA10479A (fr)
PT (1) PT788496E (fr)
RO (1) RO118715B1 (fr)
SK (1) SK281908B6 (fr)
TR (1) TR199501295A2 (fr)
WO (1) WO1996013499A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010023729A (ko) * 1997-11-03 2001-03-26 디르크 반테 지질 저하제 조성물
PL358909A1 (en) * 1998-04-27 2004-08-23 Janssen Pharmaceutica N.V. Pellets having a core coated with a lipid lowering agent and a polymer
NZ512891A (en) 1998-12-22 2003-01-31 Janssen Pharmaceutica Nv S-oxide lipid lowering compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US20050132022A1 (en) * 2003-12-12 2005-06-16 International Business Machines Corporation Computer system with LAN-based I/O
JP4994043B2 (ja) * 2004-01-21 2012-08-08 エランコ・アニマル・ヘルス・アイルランド・リミテッド ミトラタピデ経口用溶液
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005230397B2 (en) * 2004-04-09 2010-04-08 Elanco Animal Health Ireland Limited Intermittent dosing regimen for the treatment of overweight with MTP-inhibitors
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP1890767A2 (fr) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combinaison d'un antagoniste des recepteurs cannabinoides-1 et d'un inhibiteur des proteines microsomales de transfert de triglycerides pour traiter l'obesite ou maintenir une perte de poids
CA2617654A1 (fr) * 2005-08-04 2007-02-08 Pfizer Limited Composes piperidinoyl-pyrrolidine et piperidinoyl-piperidine
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007096763A2 (fr) * 2006-02-23 2007-08-30 Pfizer Limited Pipéridinoylpyrrolidines en tant qu'agonistes du récepteur de la mélanocortine de type 4
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
ES2348530T3 (es) 2007-05-25 2010-12-09 Janssen Pharmaceutica, N.V. Síntesis mejorada de metanosulfonato de (2s-cis)-2-(bromometil)-2-(4-clorofenil)-1,3 dioxolan-4-metanol (éster).
KR101280786B1 (ko) * 2008-08-06 2013-07-05 화이자 리미티드 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물
US9040539B2 (en) * 2010-05-19 2015-05-26 Sandoz Ag Process for the preparation of chiral triazolones
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313953A (en) * 1978-06-23 1982-02-02 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (fr) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derives des ({4-¬4-(4-phenyl-1-piperazinyl)-phenoxymethyl|- 1,3-dioxolan-2-yl}methyl)-1h-imidazoles et 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (fr) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibant les 4-(4-phenyl-1-piperazinyl)phenols
AU6359594A (en) * 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
DK0788496T3 (da) 2001-06-18
HUT77360A (hu) 1998-03-30
FI119548B (fi) 2008-12-31
FI971784A0 (fi) 1997-04-25
MX9703074A (es) 1997-07-31
AU697744C (en) 2002-08-22
HU219862B (hu) 2001-08-28
CA2203274C (fr) 2002-02-19
CA2203274A1 (fr) 1996-05-09
NO311937B1 (no) 2002-02-18
JP3025907B2 (ja) 2000-03-27
BR9509436A (pt) 1998-01-06
JPH09511759A (ja) 1997-11-25
DE69519995D1 (en) 2001-03-01
KR100227231B1 (ko) 1999-11-01
AU3868095A (en) 1996-05-23
CZ119897A3 (cs) 1998-03-18
EP0788496A1 (fr) 1997-08-13
CN1068000C (zh) 2001-07-04
BG63694B1 (bg) 2002-09-30
EP0788496B1 (fr) 2001-01-24
LU91306I2 (fr) 2007-03-19
PT788496E (pt) 2001-07-31
ATE198889T1 (de) 2001-02-15
NZ295353A (en) 1998-08-26
TR199501295A2 (tr) 1996-06-21
DE122007000005I1 (de) 2007-04-26
NO971895L (no) 1997-04-24
FI971784L (fi) 1997-04-25
IL115771A (en) 2000-02-29
DE122007000005I2 (de) 2008-04-24
HRP950532A2 (en) 1997-08-31
OA10479A (en) 2002-04-09
CZ286476B6 (en) 2000-04-12
DE69519995T2 (de) 2001-08-23
AP9700968A0 (en) 1997-04-30
AP779A (en) 1999-11-03
NO971895D0 (no) 1997-04-24
GR3035519T3 (en) 2001-06-29
RO118715B1 (ro) 2003-09-30
ES2155535T3 (es) 2001-05-16
WO1996013499A1 (fr) 1996-05-09
US5929075A (en) 1999-07-27
CN1161695A (zh) 1997-10-08
AU697744B2 (en) 1998-10-15
CY2256B1 (en) 2003-07-04
BG101402A (en) 1997-10-31
SK50797A3 (en) 1998-04-08
IL115771A0 (en) 1996-01-19
SK281908B6 (sk) 2001-09-11

Similar Documents

Publication Publication Date Title
AP9700968A0 (en) Apolipoprotein-B synthesis inhibitors
PL321759A1 (en) Novel thrombosin inhibitors
GB9511694D0 (en) Benzamide derivatives
GB9511935D0 (en) Novel compound
ZA959084B (en) Apolipoprotein-b synthesis inhibitors
HU9503783D0 (en) Squvalen syntetase inhibitors
DE69523450D1 (en) Inhibitor
GB9413710D0 (en) Chiral synthesis
IL112244A0 (en) Novel inhibitor
GB9522007D0 (en) New compound
EP0747449A4 (fr) Compose bisazo
ZA9610588B (en) Diamond synthesis
GB9504366D0 (en) Benzamide derivatives
GB9504868D0 (en) Benzamide derivatives
ZA981321B (en) Novel use of azoles
GB9525105D0 (en) New compound
GB9508745D0 (en) New compound
GB9512972D0 (en) New compound
GB9515162D0 (en) New compound
GB9516647D0 (en) New compound
GB9508826D0 (en) New Compound
GB9524266D0 (en) New compound
GB9505437D0 (en) New compound
GB9507254D0 (en) New compound
GB9512964D0 (en) New compound

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20111022

Year of fee payment: 17

PPPP Transfer of rights

Owner name: ELANCO ANIMAL HEALTH IRELAND LIMITED, IE

PBON Lapse due to non-payment of renewal fee

Effective date: 20121028